韩国供货方突然发来《解约函》，江苏吴中“童颜针”独家代理权生变

Core Viewpoint - Jiangsu Wuzhong's subsidiary, Datou Medical, has received a termination letter from Regen Biotech, which demands the cancellation of Datou Medical's exclusive distribution rights for the AestheFill product in mainland China, raising concerns about the company's future in the medical aesthetics sector amid ongoing financial scandals [1][2]. Group 1: Company Response and Legal Actions - Jiangsu Wuzhong has initiated a response plan upon receiving the termination letter and is in communication with Regen, indicating that legal action may be taken if necessary to protect its rights [2]. - Regen's reasons for termination include allegations that Datou Medical transferred exclusive distribution rights to its parent company, and concerns over Jiangsu Wuzhong's legal violations affecting the product's reputation [2]. Group 2: Market Impact and Financial Performance - The change in the registration agent for AestheFill from Datou Medical to Lizhen (Beijing) Biotechnology Co., owned by Regen, introduces uncertainty regarding the previously secure exclusive distribution agreement [4]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion yuan, a decline of 28.64% year-on-year, with the medical aesthetics segment generating 330 million yuan, a significant increase of over 40 times [4]. - If the exclusive distribution agreement is ultimately terminated, Datou Medical would lose its rights to sell AestheFill, leading to a substantial decrease in revenue and profit for the medical aesthetics segment in the latter half of the year [5].